• Type 2 DM.
  • Reducing the risk of cardiovascular death in adults with type 2 DM and established cardiovascular disease.
    • Starting dose: PO 10mg/5mg OD in the morning
      • Can be increased to 25mg/5mg

Tablet:

  • 10mg/5mg
  • 25mg/5mg
  • Ensure proper hydration while taking this medication due to the potential for dehydration with empagliflozin.
  • Taken without regards to meals.

Linagliptin: Dipeptidyl peptidase-4 (DPP-4) inhibitor. It inhibits the DPP-4 enzyme, increasing incretin levels (GLP-1 and GIP), which inhibit glucagon release and stimulate insulin secretion, lowering blood glucose levels.

Empagliflozin: Sodium-glucose co-transporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, leading to lower blood glucose levels.

  • UTI
  • Genital mycotic infection
  • Nasopharyngitis
  • hypoglycemia
  • Upper respiratory tract infection
  • Increased urination
  • Dyslipidemia
  • Increased hematocrit levels
  • Diarrhoea
  • Arthralgia
  • Hyperuricemia
  • Hyperlipasemia
  • Nausea
  • Cough
  • Increased creatine
  • Severe renal impairment
  • End-stage renal disease
  • Dialysis
  • Diabetic ketoacidosis
  • Volume depletion
  • eGFR <30
  • Type 1 DM
  • Insulin
  • Sulfonylureas
  • Rifampin
  • Diuretics

                                   Drug Status

Availability Prescription only
Pregnancy Contraindicated in 2nd and 3rd trimester
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Limvesta-EMP 25mg/5mg Tablet 28’s Q Pharma DMCC Harley’s Ltd
Limvesta-EMP 10mg/5mg Tablet 28’s Q Pharma DMCC Harley’s Ltd
Xempalin 10mg/5mg Tablet 20’s Biopharma Labs Tiba Healthcare
Xempalin 25mg/5mg Tablet 20’s Biopharma Labs Tiba Healthcare